Top 5 Regional Bank Stocks To Watch Right Now

Top 5 Regional Bank Stocks To Watch Right Now: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial produc! ts include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fos t er City, California.

Advisors' Opinion:

• [By Ben Levisohn]

  Like Bernstein yesterday, JPMorgan’s Geoff Meacham and team also think Gilead Sciences (GILD) will beat forecasts when it releases its financial results on Jul 23:

  Special to The Chronicle

  Gilead will report 2Q14 earnings on 23rd July, and will host a conference call at 4:30 PM ET. We are raising our 2Q non-GAAP EPS estimate to $1.73 from $1.32 (cons $1.71) and total product sales estimate to $5,618M (cons: $5,7440M). This is based primarily on increasing our 2Q Sovaldi sales estimate to $2.75B from $1.8B previously (cons: $2.92B). We expect focus on the call to be on the Sovaldi launch considering recent pricing concerns. We also expect focus to be on HIV sales trends and expectations from ADAP in 2014 as well as late stage pipeline opportunities.

  And it’s not just Gilead that Meacham is feeling good about. He’s also optimistic about Biogen Idec (BIIB), Ironwood Pharmaceuticals (IRWD) and Alexion Pharmaceiticals (ALXN):

  Our outlook for the sector remains positive (but selective) driven by what should be a good 2Q earnings season and meaningful clinical/regulatory catalysts across the sector in 2H14. Sector-leading drug launches such as Sovaldi and Tecfidera should do well in 2Q, which could help shift sentiment more positively. Overall, we continue to favor commercial stage companies with underappreciated pipeline opportunities and compelling risk / reward profiles ahead of 2Q earnings season…We like…Biogen Idec for robust mid stage pipeline and Tecfidera sales, where we again expect good upside. For Ironwood Pharmaceuticals, the DTC campaign is having a meaningful impact on demand for Linzess, and for Aexion Pharmaceuticals, we anticipate strong Soliris trends with asfotase alfa gaining focus looking to late 2014.

  Shares of Gi! lead Scie! nces have dipped 0.1% to $86.95 at 11:46 a.m., while Biogen Idec has gained 0.5% to $305.17, Alexion Pharmaceuticals has fallen 0.6% to $157.77 and Ironwood Pharmaceut

• [By Melvin Backman]

  But Olysio is just one part of a common treatment and is typically prescribed with Gilead Science' (GILD)s Sovaldi drug. Gilead is working on an Olysio replacement that will render Olysio's continued growth unsustainable, according to Royal Bank of Canada's Glenn Novarro.

• [By Ben Levisohn]

  It’s been a painful day for most biotech stocks after Janet Yellen said that smaller ones look pricey. And even Gilead Sciences (GILD) has plunged, despite the fact that Johnson & Johnson (JNJ) earnings hinted at big sales for hepatitis C drug Sovaldi.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-regional-bank-stocks-to-watch-right-now-2.html